The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
REGENXBIO Inc. (RGNX) has made remarkable progress in being able to advance its pipeline with various types of gene therapies. The last time I wrote about this article it was in a Seeking Alpha ...
Sarepta Therapeutics says its RNA therapy for Duchenne muscular dystrophy (DMD) could be more effective than its existing drugs, but a dose-escalation study also dug up some new—and serious—adverse ...
The DMD/MBA program is an integrative, four-year degree that combines business courses with the DMD curricula. Students start their business classes the summer before dentistry school. The remaining ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
REGENXBIO faces regulatory setbacks for its rare disease drugs, with cash extending only into early 2027. See why RGNX stock ...
Graz, Austria--(Newsfile Corp. - June 27, 2025) - DMD Diamond, an innovative Layer 1 blockchain founded in 2013, is proud to announce the launch of its grant program. This initiative aims to ...
Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks Consensus Estimate of a loss of 15 cents. Earnings rose 99% year over year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results